MEDI 5884

Drug Profile

MEDI 5884

Alternative Names: MEDI5884

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Developer MedImmune
  • Class Cardiovascular therapies; Macromolecular substances
  • Mechanism of Action Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders

Most Recent Events

  • 28 Nov 2017 MedImmune plans a phase II trial for Ischaemic (Coronary) heart disease (NCT03351738) (CTP#290744)
  • 19 Dec 2016 MedImmune plans a first-in-human phase I trial in Healthy volunteers in USA (SC) (NCT03001297)
  • 23 Nov 2016 Preclinical trials in Undefined indication in USA (SC) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top